BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 10338002)

  • 21. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.
    Iwasaki T; Sugisaki C; Nagata K; Takagi K; Takagi A; Kojima T; Ito M; Nakamura S; Naoe T; Murate T
    Pathol Int; 2007 Oct; 57(10):645-51. PubMed ID: 17803653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis.
    Galimberti S; Guerrini F; Carulli G; Fazzi R; Palumbo GA; Morabito F; Petrini M
    Eur J Haematol; 2004 Jan; 72(1):45-51. PubMed ID: 14962262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor.
    Liu JJ; Wang ZY; Deuel TF; Xu YH
    Biochem Biophys Res Commun; 1999 Jan; 254(1):197-9. PubMed ID: 9920757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
    Uzunel M; Ringdén O
    Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The Wilms' tumor suppressor gene WT1].
    Akiyama T
    Tanpakushitsu Kakusan Koso; 1997 Jul; 42(10 Suppl):1612-7. PubMed ID: 9279088
    [No Abstract]   [Full Text] [Related]  

  • 26. Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions.
    Luo P; Jing W; Yi K; Wu S; Zhou F
    Leuk Lymphoma; 2020 Sep; 61(9):2059-2067. PubMed ID: 32401109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features.
    Mrowka C; Schedl A
    J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S106-15. PubMed ID: 11065340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the Wilms' tumor gene (WT1) in human leukemias.
    Miwa H; Beran M; Saunders GF
    Leukemia; 1992 May; 6(5):405-9. PubMed ID: 1317488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice.
    Smith SI; Down M; Boyd AW; Li CL
    Cancer Res; 2000 Feb; 60(4):808-14. PubMed ID: 10706085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
    Iben S; Royer-Pokora B
    Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.
    Loeb DM; Evron E; Patel CB; Sharma PM; Niranjan B; Buluwela L; Weitzman SA; Korz D; Sukumar S
    Cancer Res; 2001 Feb; 61(3):921-5. PubMed ID: 11221883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
    Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
    J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 gene alterations in human hematological malignancies: a review.
    Soussi T; Jonveaux P
    Nouv Rev Fr Hematol (1978); 1991; 33(6):477-80. PubMed ID: 1818301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular cytogenetic aspects of hematological malignancies: clinical implications.
    Chen Z; Sandberg AA
    Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance.
    King-Underwood L; Pritchard-Jones K
    Blood; 1998 Apr; 91(8):2961-8. PubMed ID: 9531607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation analysis of the WT1 gene in myelodysplastic syndromes.
    Hosoya N; Miyagawa K; Mitani K; Yazaki Y; Hirai H
    Jpn J Cancer Res; 1998 Aug; 89(8):821-4. PubMed ID: 9765617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia.
    Yamauchi T; Matsuda Y; Takai M; Tasaki T; Hosono N; Negoro E; Ikegaya S; Takagi K; Kishi S; Yoshida A; Urasaki Y; Ueda T
    Anticancer Res; 2012 Oct; 32(10):4479-83. PubMed ID: 23060576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WT1: what has the last decade told us?
    Little M; Holmes G; Walsh P
    Bioessays; 1999 Mar; 21(3):191-202. PubMed ID: 10333728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.